Skip to main content

Table 1 Cost and effectiveness with baseline parameters

From: Health economic evaluation of moist wound care in chronic cutaneous leishmaniasis ulcers in Afghanistan

  Health states Av. Total
Non-compliant Primary closure No primary closure Final closure No final closure
Probability of health states
 WHO EMRO protocola 0.39 0.48 0.03 0.08 0.03 1.00
 Group I 0.39 0.48 0.03 0.08 0.03 1.00
 Group II 0.28 0.62 0.01 0.06 0.03 1.00
 Group III 0.26 0.51 0.01 0.06 0.16 1.00
Direct medical cost
 Group I (US$) 0.87 3.48 3.48 4.93 4.93 2.63
 Group II (US$) 0.81 3.26 28.31 6.26 23.40 3.58
 Group III (US$) 1.05 4.21 28.14 8.02 24.53 7.09
Injections/dressings
 WHO EMROa (N =) 2 8 8 13 13 6
 Group I (N =) 3 12 12 17 17 9
 Group II (N =) 3 11 101 21 72 12
 Group III (N =) 4 15 101 28 73 23
Drug cost
 WHO EMROa (US$) 1.32 5.28 5.28 8.58 8.58 4.11
 Group I (US$) 0.40 1.58 1.58 2.24 2.24 1.20
 Group II (US$) 0.47 1.87 17.17 3.57 12.24 2.03
 Group III (US$) 0.64 2.55 17.17 4.76 12.41 3.90
Direct non-medical cost
 Group I (US$) 1.36 7.70 7.70 9.97 9.97 5.50
 Group II (US$) 1.88 10.26 69.22 17.57 49.59 10.05
 Group III (US$) 2.23 11.29 60.12 19.35 43.47 15.02
Indirect cost
 Group I (US$) 5.82 1.32 5.82 1.61 5.29 3.31
 Group II (US$) 5.82 0.63 5.82 1.64 4.80 2.32
 Group III (US$) 5.82 0.86 5.82 1.61 5.07 2.90
Total average cost
 Group I (US$) 8.05 12.50 17.00 16.51 20.19 11.43
 Group II (US$) 8.51 14.15 103.35 25.47 77.79 15.91
 Group III (US$) 9.10 16.36 94.08 28.98 73.07 24.97
Wound free days
 Group I (WFD) 0 234 0 207 0 129
 Group II (WFD) 0 270 0 167 0 177
 Group III (WFD) 0 258 0 233 0 147
ICER
 Group I (US$/WFD) N.A. 0.00 N.A. 0.00 N.A. 0.00
 Group II (US$/WFD) N.A. 0.05 N.A. −0.22 N.A. 0.09
 Group III (US$/WFD) N.A. 0.16 N.A. 0.48 N.A. 0.77
NMB (WTP = 1.92)
 Group I (US$) −8 437 −17 381 −20 236
 Group II (US$) −9 504 − 103 295 − 78 324
 Group III (US$) −9 479 −94 418 −73 257
  1. All costs in 2013 US$
  2. a WHO EMRO protocol is defined as 1 to 5 ml IL SSG, twice weekly for three to 4 weeks [4]. The probability of health states of Group I was also assumed for the IL SSG WHO EMRO protocol, as a best guess. We assumed a mean IL SSG dosage of 3 ml per injection and 5 additional injections for final closure based on the IL SSG re-ulceration time found in Stahl et al. [3]